Navigation Links
Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
Date:2/11/2008

products; ability to comply with applicable regulatory requirements; history of losses and ability to achieve sustained profitability; volatility of our stock price; uncertainty relating to patent protection; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally; loss or impairment of sources of capital; ability to meet financial covenants in agreements with financial institutions; ability to retain qualified personnel; exposure to patent infringement, product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; ability to complete consolidation or restructuring activities; ability to identify, complete and realize the full benefits of potential acquisitions; and general political, business and economic conditions. These and other factors are discussed more fully in the Securities and Exchange Commission ("SEC") filings of OraSure Technologies, including its registration statements, its Annual Report on Form 10-K for the year ended December 31, 2006, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Although forward-looking statements help to provide complete information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. OraSure Technologies undertakes no duty to update any forward-looking statements after they are made.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with p
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
2. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
3. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
6. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
7. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
8. Schering-Plough Completes Acquisition of Organon BioSciences
9. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
10. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
11. Schering-Plough Announces Pricing of Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 The ... the back of the recession and high prices in ... market has recovered and keeps on gaining momentum now. ... NPK stands at more than 100,000 thousand tonnes. No ... years. Meantime, the global capacity rocketed during 2012-2013, registering ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... leader in liquid photopurification, announced today that the ... approval for the continued trading of SurePure ("SURP") ... execution venture marketplace for entrepreneurial and development stage ... Markets Group introduced standards and eligibility requirements designed ...
(Date:3/27/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the global pharmaceutical, biotechnology, ... Investigational New Drug (IND) application for WuXi MedImmune,s ... been accepted for review by the China Food ... September 2012, MedImmune, the global biologics research and ...
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7
... Mass. Much of the work in MIT Institute Professor ... pages of science fiction, but its products are already saving ... One of Langers specialties is growing the vital tissues of ... organs such as the liver and intestinesin a laboratory dish ...
... Conn., Feb. 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ... February 15, 2008 on its 7.75% Convertible Senior Notes,due ... Notes is $60,million., The Company paid $2,376,666.67 through ... $2,376,345.60 was paid in 5,500,800,shares of Common Stock, based ...
... ROCHESTER, N.Y., Feb. 15 EUSA Pharma (Oxford, ... has licensed OP-R003,a human anti-interleukin-6 antibody discovered by ... the product license, GSK will pay an up-front,license ... to,acquire the exclusive world-wide rights to develop and ...
Cached Biology Technology:MIT researcher addresses biomedical engineering challenges 2MIT researcher addresses biomedical engineering challenges 3Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2Vaccinex Antibody Licensed to GlaxoSmithKline 2
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... Switching off a key DNA repair system in the developing ... as problems in brain structures vital to movement, memory and ... Research Hospital scientists. The work, published in the August ... the first evidence that cells known as cerebellar interneurons are ...
... cancer survivors who are interested in diet and exercise actually ... those survivors who do exercise and watch their diet have ... September 1, 2009 issue of Cancer , a peer-reviewed ... greater efforts are needed to encourage elderly cancer survivors to ...
... Scientists are closer to understanding how to grow replacement ... in the journal Nature Materials . Many ... stem cells, to implant into patients who have damaged or ... removed. The idea is that, ultimately, these bone-like materials could ...
Cached Biology News:Scientists track impact of DNA damage in the developing brain 2Scientists track impact of DNA damage in the developing brain 3Most older long-term cancer survivors have poor health habits 2Scientists closer to making implantable bone material, thanks to new research 2
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
P8B1...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Biology Products: